Advanced Enzyme Technologies Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Mukund Kabra
Chief Executive Officer (CEO)
₹24.3m
Compensación total
| Porcentaje del salario del CEO | 25.1% |
| Permanencia del CEO | 24.7yrs |
| Participación del CEO | 1.6% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 5.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
Jul 13
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
Apr 08Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Sep 23Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Feb 03Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Aug 11With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
May 13Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
Mar 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
Mar 13Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
Feb 21Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 18I Built A List Of Growing Companies And Advanced Enzyme Technologies (NSE:ADVENZYMES) Made The Cut
Feb 03
What Kind Of Investors Own Most Of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)?
Jan 19What Do The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Tell Us?
Dec 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 114%, So Why Not Pay It Some Attention?
Dec 13Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Nov 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Advanced Enzyme Technologies Limited's NSE:ADVENZYMES) Stock?
Nov 20Here's Why I Think Advanced Enzyme Technologies (NSE:ADVENZYMES) Might Deserve Your Attention Today
Nov 05What You Need To Know About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Investor Composition
Oct 21Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Oct 06Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Stocks Shoot Up 31% But Its P/E Still Looks Reasonable
Sep 26Our Take On The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES)
Sep 21Does Advanced Enzyme Technologies (NSE:ADVENZYMES) Have A Healthy Balance Sheet?
Sep 08Have Insiders Sold Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Recently?
Aug 26Why We're Not Concerned About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price
Aug 21Introducing Advanced Enzyme Technologies (NSE:ADVENZYMES), A Stock That Climbed 60% In The Last Year
Aug 20Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) P/E Is On The Mark
Aug 07Are Insiders Buying Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Stock?
Jul 29How Does Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Fare As A Dividend Stock?
Jul 17Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Jul 04Do Advanced Enzyme Technologies's (NSE:ADVENZYMES) Earnings Warrant Your Attention?
Jun 28Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | ₹1b |
| Sep 30 2023 | n/a | n/a | ₹1b |
| Jun 30 2023 | n/a | n/a | ₹1b |
| Mar 31 2023 | ₹24m | ₹6m | ₹1b |
| Dec 31 2022 | n/a | n/a | ₹979m |
| Sep 30 2022 | n/a | n/a | ₹960m |
| Jun 30 2022 | n/a | n/a | ₹995m |
| Mar 31 2022 | ₹22m | ₹6m | ₹1b |
| Dec 31 2021 | n/a | n/a | ₹1b |
| Sep 30 2021 | n/a | n/a | ₹1b |
| Jun 30 2021 | n/a | n/a | ₹1b |
| Mar 31 2021 | ₹21m | ₹5m | ₹1b |
| Dec 31 2020 | n/a | n/a | ₹1b |
| Sep 30 2020 | n/a | n/a | ₹1b |
| Jun 30 2020 | n/a | n/a | ₹1b |
| Mar 31 2020 | ₹19m | ₹5m | ₹1b |
| Dec 31 2019 | n/a | n/a | ₹1b |
| Sep 30 2019 | n/a | n/a | ₹1b |
| Jun 30 2019 | n/a | n/a | ₹1b |
| Mar 31 2019 | ₹17m | ₹4m | ₹1b |
| Dec 31 2018 | n/a | n/a | ₹1b |
| Sep 30 2018 | n/a | n/a | ₹1b |
| Jun 30 2018 | n/a | n/a | ₹1b |
| Mar 31 2018 | ₹15m | ₹4m | ₹901m |
Compensación vs. Mercado: La compensación total ($USD291.08K) de Mukund está en línea con el promedio de empresas de tamaño similar en el mercado Indian ($USD278.32K).
Compensación vs. Ingresos: La compensación de Mukund ha sido consistente con los resultados de la empresa en el último año.
CEO
Mukund Kabra (51 yo)
24.7yrs
Permanencia
₹24,250,932
Compensación
Mr. Mukund Madhusudan Kabra serves as a Whole Time Director at Advanced Enzyme Technologies Ltd. since April 1, 2009 and also served as its Director since September 4, 1999. Mr. Kabra began at the junior-m...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Whole Time Director | 24.7yrs | ₹24.25m | 1.63% ₹ 705.9m | |
| Independent Director | 1.8yrs | ₹380.00k | sin datos | |
| Non-Executive Director | 4.5yrs | ₹330.00k | sin datos | |
| Independent Non-Executive Director | 7.4yrs | ₹1.26m | 0.0045% ₹ 1.9m | |
| Chairman | 31.2yrs | ₹990.00k | 38.68% ₹ 16.7b | |
| Additional Non-Executive Director | 5.3yrs | ₹580.00k | 2.38% ₹ 1.0b | |
| Independent Director | 5.3yrs | ₹940.00k | sin datos | |
| Independent Director | 3.9yrs | ₹730.00k | sin datos | |
| Independent Director | less than a year | sin datos | sin datos |
5.3yrs
Permanencia media
54yo
Promedio de edad
Junta con experiencia: La junta directiva de ADVENZYMES se considera experimentada (5.2 años de antigüedad promedio).